Decline in major deals in the biopsy equipment division
First written in FY2019-Q2. 5 of 10 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023DroppedAnnual reportThe full-year discussion of the biomedical equipment segment for the current fiscal year does not identify an increase or decrease in major orders as an independent performance factor.
- FY2022RestatedAnnual report
「Sales of electrocardiograph-related products increased, but large-scale business negotiations declined. Consolidated sales were ¥29,422 million, and segment profit was ¥4,129 million, up 25.1% year on year.」
Reconfirms that, despite sales growth in electrocardiography-related products, a decline in major orders is affecting performance in the biomedical equipment segment. - FY2022-Q2RestatedAnnual report
「Sales of electrocardiograph-related products increased, but large-scale business negotiations declined. Consolidated sales were ¥12,268 million, and operating profit was ¥1,600 million, up 53.6% year on year.」
Reconfirms that, despite sales growth in electrocardiography-related products, a decline in major orders is affecting performance in the biomedical equipment segment. - FY2021RestatedAnnual report
「Consolidated net sales were ¥40.445 billion, up 5.8% year on year, driven by higher major orders.」
Reconfirms that major orders, which had been recorded as a negative factor in the previous fiscal year, turned to an increase and supported full-year sales in the biomedical equipment segment. - FY2021-Q3Higher major orders, lower IT-related product salesAnnual report
「Although sales of electrocardiograph-related products and IT-related products declined, large-scale business negotiations increased, resulting in consolidated sales of ¥26,738 million, up 3.9% year on year, and operating profit of ¥1,878 million, up 17.0%.」
While IT-related products, which had been recorded as a source of revenue growth through the previous quarter, turned to a decline, higher major orders continue to support performance in the biomedical equipment segment. - FY2020-Q3Major orders and IT growth continue, but growth slowsAnnual report
「Growth in large-scale business negotiations and IT-related products drove consolidated sales to ¥25,730 million, up 6.0% year on year, and operating profit to ¥1,605 million, up 2.7%.」
Major orders, which were recorded as a negative factor in the previous fiscal year, turned to an increase, and growth in IT-related products continued. However, the segment's growth rate slowed compared with the cumulative results through the previous quarter. - FY2020-Q2RestatedAnnual report
「Growth in large-scale business negotiations and IT-related products drove consolidated sales to ¥19,127 million, up 22.0% year on year, and operating profit to ¥1,319 million, up 24.5%.」
In the biomedical equipment segment, higher major orders continue to support performance. - FY2020-Q1Major orders changed from a decline to an increaseAnnual report
「Sales of electrocardiography-related products and automated hematology analyzers declined, but overall sales increased due to higher major orders, resulting in consolidated net sales of ¥6.892 billion, up 3.8% year on year.」
The situation has changed from the decline in major orders recorded in the previous fiscal year to one in which higher major orders are driving growth in the biomedical equipment segment. - FY2019RestatedAnnual report
「Although sales of electrocardiography-related products increased, consolidated net sales were ¥38.912 billion, down 0.9% year on year, due to a decline in major orders.」
Reconfirms that, despite sales growth in electrocardiography-related products, a decline in major orders constrained full-year performance in the biomedical equipment segment. - FY2019-Q2First statedAnnual report
「Sales of electrocardiography-related products and automated hematology analyzers increased, but major orders declined.」
While identifying sales growth in electrocardiography-related products and automated hematology analyzers, this is the first time a decline in major orders is recorded as a performance factor for the biomedical equipment segment.